NCT02301936View on ClinicalTrials.gov

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

March 2, 2015

Primary Completion Date

April 18, 2016

Study Completion Date

April 18, 2016

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

90/400 mg fixed dose combination (FDC) tablet administered orally once daily

Trial Locations (1)

Unknown

Lutherville

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY